CGT9486-20-201: A Phase 2 Open Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (APEX)
- Sponsor:
- Cogent Biosciences
- Sponsor Study ID:
- CGT9486-20-201
- CTO #:
- 103784
- NCT Number:
- NCT04996875
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Leukemia, other; Myeloid and Monocytic Leukemia
- Study Objectives:
- To determine the optimal dose of oral CGT9486 in patients with AdvSM. To determine the efficacy of CGT9486 at the selected optimal dose in patients with AdvSM.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Williams, Kelli, at williamske@musc.edu .
- Study Coordinator, Naylon, Natalie, at naylon@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina